Treatment of alcohol withdrawal with gabapentin

Bozikas, Vasilis P.; Petrikis, Petros; Gamvrula, Katerina; Savvidou, Ioanna; Karavatos, Athanasios

doi:10.1016/s0278-5846(01)00234-2

Cited by 64 publications

(37 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the basis of promising data from animal experiments (Watson et al, 1997;Bailey et al, 1998;Dooley et al, 2000), preliminary clinical studies were designed to establish the possible efficacy of gabapentin in the treatment of alcohol-dependent patients affected by AWS. Open-label studies suggest a generally positive effect of gabapentin in AWS (Myrick and Anton, 1998;Bonnet et al, 1999Bonnet et al, , 2003Bonnet et al, , 2010Chatterjee and Ringold, 1999;Bozikas et al, 2002). A retrospective study analyzed both out-and inpatients treated with gabapentin (starting dose 1200 mg daily) in the treatment of AWS.…”

Section: Gabapentinmentioning

confidence: 99%

Novel Therapeutic Strategies for Alcohol and Drug Addiction: Focus on GABA, Ion Channels and Transcranial Magnetic Stimulation

Addolorato

Leggio

Hopf

et al. 2011

Neuropsychopharmacol

View full text Add to dashboard Cite

Drug addiction represents a major social problem where addicts and alcoholics continue to seek and take drugs despite adverse social, personal, emotional, and legal consequences. A number of pharmacological compounds have been tested in human addicts with the goal of reducing the level or frequency of intake, but these pharmacotherapies have often been of only moderate efficacy or act in a sub-population of humans. Thus, there is a tremendous need for new therapeutic interventions to treat addiction. Here, we review recent interesting studies focusing on gamma-aminobutyric acid receptors, voltage-gated ion channels, and transcranial magnetic stimulation. Some of these treatments show considerable promise to reduce addictive behaviors, or the early clinical studies or pre-clinical rationale suggest that a promising avenue could be developed. Thus, it is likely that within a decade or so, we could have important new and effective treatments to achieve the goal of reducing the burden of human addiction and alcoholism.

show abstract

Section: Gabapentinmentioning

confidence: 99%

Novel Therapeutic Strategies for Alcohol and Drug Addiction: Focus on GABA, Ion Channels and Transcranial Magnetic Stimulation

Addolorato

Leggio

Hopf

et al. 2011

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…Gabapentin has been used effectively in the treatment of alcohol withdrawal in alcoholics (Bonnet et al, 1999(Bonnet et al, , 2007Bozikas et al, 2002;Gentry et al, 2002;Voris et al, 2003;Book and Myrick, 2005;Mariani et al, 2006;Myrick et al, 2007) and has a selective action in decreasing the convulsive and anxiety-related signs of ethanol withdrawal in mice (Watson et al, 1997). Gabapentin decreases ethanol-induced anxiety-like behavior in the elevated plus maze, but has no effect on motor coordination or spontaneous locomotor activity in control mice (Watson et al, 1997).…”

Section: Introductionmentioning

confidence: 99%

Cellular and Behavioral Interactions of Gabapentin with Alcohol Dependence

Roberto¹,

Gilpin²,

O’Dell³

et al. 2008

J. Neurosci.

117

128

View full text Add to dashboard Cite

Gabapentin is a structural analog of GABA that has anticonvulsant properties. Despite the therapeutic efficacy of gabapentin, its molecular and cellular mechanisms of action are unclear. The GABAergic system in the central nucleus of the amygdala (CeA) plays an important role in regulating voluntary ethanol intake. Here, we investigated the effect of gabapentin on GABAergic transmission in CeA slices, on ethanol intake, and on an anxiety measure using animal models of ethanol dependence. Gabapentin increased the amplitudes of evoked GABA receptor-mediated IPSCs (GABA-IPSCs) in CeA neurons from nondependent rats, but decreased their amplitudes in CeA of ethanol-dependent rats. Gabapentin effects were blocked in the presence of a specific GABA B receptor antagonist. The sensitivity of the GABA-IPSCs to a GABA B receptor antagonist and an agonist was decreased after chronic ethanol, suggesting that ethanol-induced neuroadaptations of GABA B receptors associated with ethanol dependence may account for the differential effects of gabapentin after chronic ethanol. Systemic gabapentin reduced ethanol intake in dependent, but not in nondependent, rats and reversed the anxiogeniclike effects of ethanol abstinence using an acute dependence model. Gabapentin infused directly into the CeA also blocked dependenceinduced elevation in operant ethanol responding. Collectively, these findings show that gabapentin reverses behavioral measures of ethanol dependence and, in turn, dependence reverses the effects of gabapentin on CeA neurons, and suggest that gabapentin represents a potential medication for treatment of alcoholism.

show abstract

“…Estudos preliminares evidenciaram a eficácia no tratamento da SAA (Myrick et al, 1998;Bozikas et al, 2002) e da SDA, particularmente os casos de leve a moderada gravidade (Bonnet et al, 1999;Myrick e Anton, 2004).…”

Section: Gabapentinaunclassified

Uso potencial dos anticonvulsivantes no tratamento ambulatorial da dependência de álcool

Castro

Couzi

2006

J. bras. psiquiatr.

View full text Add to dashboard Cite

ResumoAtualmente três medicações (dissulfiram, naltrexona e acamprosato) são aprovadas pela Food and Drug Administration (FDA) para tratar a dependência de álcool. As drogas anticonvulsivantes clássicas são raramente empregadas como alternativa por causa dos seus efeitos colaterais, mas a sua última geração pode ser útil. Os anticonvulsivantes podem ser uma alternativa aos benzodiazepínicos (BZD) e a outros tratamentos farmacoló-gicos na prevenção de complicações na desintoxicação por apresentarem ausência de propriedades aditivas e um melhor perfil de efeitos adversos do que os anticonvulsivantes clássicos. Anticonvulsivantes como carbamazepina, ácido valpróico, gabapentina e topiramato demonstraram-se excelentes tratamentos para síndrome de abstinência do álcool e prevenção de recaídas. Embora nenhum desses agentes tenha sido aprovado pela FDA, existe uma crescente evidência na literatura que apóia o seu uso. Palavras-chave: anticonvulsivantes, alcoolismo, carbamazepina, ácido valpróico. AbstractCurrently three medications (disulfiram, naltrexone and acamprosate) are approved by the FDA to treat alcohol dependence by the FDA. The classical anticonvulsive drugs are rarely employed as an alternative because of their side effects, but the latest generation of anticonvulsants could be useful. The anticonvulsants can be a alternative to BZD and other pharmacological treatments in the prevention of complications during the detoxification therapy, because of the absence of addictive properties and a better adverse effects profile than classical anticonvulsant drugs. Anticonvulsants such as carbamazepine, valproic acid, gabapentin and topiramate have shown to be excellent treatment for alcohol withdrawal and for the prevention of alcohol relapse. Although none of these agents have been approved by the FDA yet, there is growing evidence in the literature to support their use.

show abstract

Treatment of alcohol withdrawal with gabapentin

Cited by 64 publications

References 15 publications

Novel Therapeutic Strategies for Alcohol and Drug Addiction: Focus on GABA, Ion Channels and Transcranial Magnetic Stimulation

Novel Therapeutic Strategies for Alcohol and Drug Addiction: Focus on GABA, Ion Channels and Transcranial Magnetic Stimulation

Cellular and Behavioral Interactions of Gabapentin with Alcohol Dependence

Uso potencial dos anticonvulsivantes no tratamento ambulatorial da dependência de álcool

Contact Info

Product

Resources

About